CD274 and non-small cell lung carcinoma: These malignant phenotypes led to the association of PD-L1 with tumor cell resistance (33), including bladder carcinoma (34), non-small-cell lung cancer (35), breast cancer (17, 36), and head and neck squamous cell carcinoma (37).